+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID04944563

Comparing Segmentectomy and Lobectomy for Early-Stage Non-Small Cell Lung Cancer Up to 2 cm in the Middle Third of the Lung

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2022-04-05

1120

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether segmentectomy is as effective as lobectomy for treating patients with early-stage non-small cell lung cancer that is 2 cm or smaller and located in the middle third of the lung. This study aims to determine if segmentectomy has similar long-term cancer control and survival outcomes compared to lobectomy, expanding on previous research focused on tumors in the outer third of the lung. Participants will be randomly assigned to receive either segmentectomy or lobectomy surgery. Both procedures aim to remove the tumor with clear margins R0 resection. The study monitors patients over several years to compare outcomes between the two surgical options. During the study, researchers will assess participants disease-free survival over five years as the main outcome. They will also track complications within 30 days after surgery, lung function during the first year, and overall survival at three and five years. The total follow-up period is up to five years after recruitment, with regular evaluations and lung function tests at specific intervals.

CONDITIONS

Brief Title

Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field

Research Team

Z

Zhihua Li, M.D.

W

Weibing Wu, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here